Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
The company uses iPS cells to develop treatments for diseases relating to the kidney
The company uses iPS cells to develop treatments for diseases relating to the kidney
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Subscribe To Our Newsletter & Stay Updated